カレントテラピー　35-9　サンプル page 11/34

このページは カレントテラピー　35-9　サンプル の電子ブックに掲載されている11ページの概要です。
秒後に電子ブックの対象ページへ移動します。
「電子ブックを開く」をクリックすると今すぐ対象ページへ移動します。

概要：
カレントテラピー　35-9　サンプル

14 Current Therapy 2017 Vol.35 No.9828拡充を図り，国民の医療ないし予防医学の向上に寄与することを目的としている．他の遺伝性腫瘍の先駆けとなり，わが国の癌および遺伝診療の進歩への貢献が期待される．参考文献1）国立がん研究センターがん情報サービス（http://ganjoho.jp/reg_stat/statistics/stat/short_pred.html）（2017年6月閲覧）2）Gene Reviews BRCA1-and BRCA2-Associated HereditaryBreast and Ovarian Cancer （https://www.ncbi.nlm.nih.gov/books/NBK1247/）（2017年6月閲覧）3）Verhoog LC, Brekelmans CT, Seynaeve C, et al：Survival inhereditary breast cancer associated with germline mutationsof BRCA2. J Clin Oncol 17：3396-3402, 19984）Verhooq LC, Brekelmans CT, Seynaeve C, et al：Survivaland tumor characteristics of breast -cancer patients withgermline mutations of BRCA1. Lancet 351：316-321, 19985）Leongamornlert D, Mahmud N, Tymrakiewicz M, et al：Germline BRCA1 mutations increase prostate cancer risk. BrJ Cancer 106：1697-1701, 20126）Kote-Jarai Z, Leongamornlert D, Saunders E, et al：BRCA2is a moderate penetrance gene contributing to young-onsetprostate cancer：implications for genetic testing in prostatecancer patients. Br J Cancer 105：1230-1234, 20117）Mavaddat N, Barrowdale D, Andrulis IL, et al：Pathology ofbreast and ovarian cancers among BRCA1 and BRCA2 mutationcarriers：results from the Consortium of Investigators ofModifiers of BRCA1/2（CIMBA）. Cancer Epidemiol BiomarkersPrev 21：134-147, 20128）Castro E, Goh C, Olmos D, et al：Germline BRCA mutationsare associated with higher risk of nodal involvement, distantmetastasis, and poor survival outcome in prostate cancer. JClin Oncol 31：1748-1757, 20139）Warner E, Hill K, Causer P, et al：Prospective Study ofBreast Cancer Incidence in Women With a BRCA1 or BRCA2Mutation Under Surveillance With and Without MagneticResonance Imaging. J Clin Oncol 29：1664-1669, 201110）Heemskerk-Gerritsen BA, Rookus MA, Aalfs CM, et al：Improved overall survival after contralateral risk-reducingmastectomy in BRCA1/2 mutation carriers with a history ofunilateral breast cancer. A prospective analysis. Int J Cancer136：668-677, 201511）Domchek SM, Friebel TM, Singer CF, et al：Association ofrisk-reducing surgery in BRCA1 or BRCA2 mutation carrierswith cancer risk and mortality. JAMA 304：967-975, 201412）Bancroft EK, Page EC, Castro E, et al：Targeted ProstateCancer Screening in BRCA1 and BRCA2 Mutation Carriers：Results from the Initial Screening Round of the IMPACTStudy. Eur Urol 66：489-499, 201413）NCCN Guidelines version2. 2017-December 7, 2016 Genetic/Familial High-Risk Assessment：Breast and Ovarian14）Miki Y, Swensen J, Shattuck-Eidens D, et al：A strong candidatefor the breast and ovarian cancer susceptibility geneBRCA1. Science 266：66-71, 199415）Wooster R, Bignell G, Lancaster J, et al：Identification of thebreast cancer susceptibility gene BRCA2. Nature 378：789-792, 199516）Melchor L, Benitez J：The complex genetic landscape offamilial breast cancer. Hum Genet 132：845-863, 201317）Buys SS, Sandbach JF, Gammon A, et al：A study of over35,000 women with breast cancer tested with a 25-genepanel of hereditary cancer genes. Cancer 123：1721-1730,201718）Tung N, Battelli C, Allen B, et al：Frequency of mutations inindividuals with breast cancer referred for BRCA1 andBRCA2 testing using next -generation sequencing with a25-gene panel. Cancer 121：25-33, 201519）Desmond A, Kurian AW, Gabree M, et al：Clinical Actionabilityof Multigene Panel Testing for Hereditary Breast andOvarian Cancer Risk Assessment. JAMA Oncol 1：943-951,2015